BrightSpring Health Azioni (NASDAQ: BTSG)

Ultime notizie per BrightSpring Health (NASDAQ:BTSG) Azioni

BrightSpring Health

BrightSpring Health Services Inc is a home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. Its platform delivers clinical services and pharmacy solutions across Medicare, Medicaid, and commercially insured populations. Its segments include Pharmacy Solutions, Provider Services and others. It generates the majority of its revenue from the Pharmacy Solutions segment.

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health Services Inc

BrightSpring Health Services, Inc. - Tangible Equity Unit

BTS GROUP HLDGS UNSP/ADR by BTS Group Holdings Public Company Ltd

BTS Group Holdings PLC

Guggenheim analyst Michael Schmidt reiterates SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) with a Neutral and maintains $47 price target.

News

Price Target

Reiteration

Analyst Ratings

SWTX

Guggenheim Reiterates Neutral on SpringWorks Therapeutics, Maintains $47 Price Target

WIIM

Gold and silver are trading lower after the US and China agreed to a temporary reduction in most tariffs on each other's goods. This could be driving a rotation out of safe-haven assets.

Barclays analyst Ramsey El-Assal maintains EPAM Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAM#NYSE">EPAM</a>) with a Overweight and raises the price target from $200 to $215.

EPAM

Barclays Maintains Overweight on EPAM Systems, Raises Price Target to $215

<a href="https://www.philips.com/a-w/about/news/archive/standard/news/articles/2025/philips-collaborates-with-nvidia-to-improve-patient-care-in-mr-with-latest-ai-advances#:~:text=Philips%20collaborates%20with%20NVIDIA%20to,MR%20with%20latest%20AI%20advances&amp;text=From%20cutting%20scan%20times%2C%20to,for%20their%20patients%20%5B1%5D.">https://www.philips.com/a-w/about/news/archive/standard/news/articles/2025/philips-collaborates-with-nvidia-to-improve-patient-care-in-mr-with-latest-ai-advances#:~:text=Philips%20collaborates%20with%20NVIDIA%20to,MR%20with%20latest%20AI%20advances&amp;text=From%20cutting%20scan%20times%2C%20to,for%20their%20patients%20%5B1%5D.</a>
&nbsp;
From cutting scan times, to speeding workflow and improving image quality, Philips is already empowering healthcare providers with AI-powered solutions to deliver faster, more accurate diagnoses for their patients [1]. Today at a major industry gathering <a href="https://www.usa.philips.com/healthcare/event/upcoming/ismrm-2025">ISMRM</a>, the company announced a new breakthrough collaboration with NVIDIA to harness cutting-edge advances in AI for MR imaging.
 &nbsp;

NVDA

Reported Earlier: 'Philips Collaborates With NVIDIA To Improve Patient Care In MR With Latest AI Advances' - Phillips

Guggenheim analyst John Heinbockel reiterates Xponential Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPOF#NYSE">XPOF</a>) with a Buy and maintains $13 price target.

XPOF

Guggenheim Reiterates Buy on Xponential Fitness, Maintains $13 Price Target

SHOP

Shopify shares are trading higher after it was announced the stock will join the Nasdaq-100 beginning May 19.

Hamilton Beach Brands Holdings shares are trading higher after the company raised its quarterly cash dividend.

Barclays analyst Brandt Montour maintains DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) with a Overweight and lowers the price target from $50 to $48.

DKNG

Barclays Maintains Overweight on DraftKings, Lowers Price Target to $48

<a href="https://www.youtube.com/watch?v=u9kS0t0jkJs" title="https://www.youtube.com/watch?v=u9kS0t0jkJs">https://www.youtube.com/watch?v=u9kS0t0jkJs</a>

Macro Economic Events

Politics

Global

Economics

General

President Trump Says China Has Agreed To Stop Fentanyl; Big Incentive For China To Stop; Take China At Their Word

Baird analyst David Koning downgrades TaskUs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TASK#NASDAQ">TASK</a>) from Outperform to Neutral and maintains the price target from $16.5 to $16.5.

Downgrades

TASK

Baird Downgrades TaskUs to Neutral, Maintains Price Target to $16.5

Blade Air Mobility Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLDE#NASDAQ">BLDE</a>) shares are trading higher on Monday after the company reported better-than-<a href="https://www.benzinga.com/pressreleases/25/05/g45343555/blade-air-mobility-announces-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">expected first-quarter 2025 results</a>.
Revenue grew&nbsp;5.4%&nbsp;year-over-year (Y/Y) to&nbsp;$54.3 million, beating the consensus of&nbsp;$49.43 million.
Revenue growth was driven by growth in the Passenger segment. Excluding Canada, which exited in August 2024, revenue increased&nbsp;10.9%&nbsp;Y/Y.
Medical revenue declined 0.2% Y/Y&nbsp;to&nbsp;$35.9&nbsp;million. Short Distance revenue fell&nbsp;5.4%&nbsp;Y/Y to&nbsp;$9.3&nbsp;million, but excluding Canada, it grew&nbsp;28.1% Y/Y.
Jet and Other revenue surged&nbsp;59.9%&nbsp;to&nbsp;$9.1&nbsp;million&nbsp;on increased flight volumes and revenue per flight.
Flight Profit rose&nbsp;18.1% Y/Y&nbsp;to&nbsp;$12.0&nbsp;million, driven by growth in Passenger segments. Flight Margin improved to&nbsp;22.1%&nbsp;from&nbsp;19.7% in the quarter.
Adjusted EBITDA improved by&nbsp;$2.3&nbsp;million&nbsp;Y/Y to&nbsp;$(1.2)&nbsp;million, driven by improvements in the Passenger segment.
Quarterly net loss improved by&nbsp;$0.7&nbsp;million&nbsp;Y/Y to&nbsp;$(3.5)&nbsp;million, mainly due to a&nbsp;$2.3 million&nbsp;improvement in operating losses.
EPS&nbsp;loss of 4 cents exceeded the street <a href="https://www.benzinga.com/earnings">view of loss of 11 cents</a>.
Operating Cash Flow rose by&nbsp;$15.3&nbsp;million&nbsp;to&nbsp;$(0.2)&nbsp;million in the quarter. Capex was&nbsp;$3.2&nbsp;million due to aircraft maintenance and purchase of aircraft in the Medical Segment.
Free Cash Flow before aircraft acquisitions improved by&nbsp;$14.0&nbsp;million&nbsp;to&nbsp;$(2.7)&nbsp;million in the quarter.
Rob Wiesenthal, Blade&#8217;s chief executive officer, said, &#8220;Our strong Passenger Segment results reflect several factors including our durable competitive positioning along with the important actions we&#8217;ve taken recently to improve profitability such as our exit from Canada and broad-based cost rationalization initiatives.&#8221;
Will Heyburn, chief financial officer added, &#8220;Our Medical business is well positioned to prosper in the current environment given the strength of our logistics platform, strong underlying transplant volume growth, limited economic sensitivity and insulation from tariffs.&#8221;
2025&nbsp;Outlook:&nbsp;Blade Air Mobility expects revenue of&nbsp;$245 million&nbsp;–&nbsp;$265 million&nbsp;versus consensus of&nbsp;$256.3 million&nbsp;and <a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44301933/blade-air-mobility-soars-as-q4-revenue-beats-expectations-and-medical-segment-shines" rel="noreferrer noopener">double-digit Adjusted EBITDA.</a>
Heyburn added, &#8220;We continue to expect improving results throughout the rest of the year in both business lines. In Medical, we are onboarding additional new customers and expect continued growth with existing customers. In Passenger, while the economic outlook may be uncertain, we still expect ongoing year-over-year benefits from cost and restructuring actions, as we will not anniversary our implementation of most items <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">until the fourth quarter of this year.</a>&#8220;
Melissa Tomkiel, president, stated, &#8220;Following a period of unusually heavy scheduled aircraft maintenance and associated downtime during the first half of 2025, we expect a significant improvement in the second half of the year through 2026, resulting in reduced capital expenditures and improved Medical Segment Adjusted EBITDA margins.&#8221;
Investors can gain exposure to the stock via&nbsp;ARK Space Exploration &amp; Innovation ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>).
Price Action: BLDE shares are up 14.7% at $3.35 at the last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/02/43781179/joby-vs-archer-vs-blade-which-evtol-stock-is-ready-for-takeoff" target="_blank" rel="noreferrer noopener">Joby Vs. Archer Vs. Blade: Which eVTOL Stock Is Ready For Takeoff?</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Earnings

Equities

Guidance

Small Cap

Movers

ARKX

BLDE

Blade Beats Q1 Forecasts As Jet Surge, Short Flights Drive Gains

Eton Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Eton Pharmaceuticals to report an earnings per share (EPS) of $0.03.
The announcement from Eton Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Past Earnings Performance</h3>
The company's EPS missed by $0.00 in the last quarter, leading to a 1.36% increase in the share price on the following day.
Here's a look at Eton Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.02</td>
<td>-0.01</td>
<td>-0.07</td>
<td>-0.07</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.02</td>
<td>0.02</td>
<td>-0.12</td>
<td>-0.03</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>16.0%</td>
<td>3.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747058590_0.png" alt="eps graph" />
<h3>Performance of Eton Pharmaceuticals Shares</h3>
Shares of Eton Pharmaceuticals were trading at $16.79 as of May 09. Over the last 52-week period, shares are up 360.74%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analysts' Perspectives on Eton Pharmaceuticals</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Eton Pharmaceuticals.
The consensus rating for Eton Pharmaceuticals is Buy, derived from 3 analyst ratings. An average one-year price target of $27.67 implies a potential 64.8% upside.
<h3>Analyzing Ratings Among Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Tilray Brands, Zevra Therapeutics and EyePoint Pharmaceuticals, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Tilray Brands, with an average 1-year price target of $1.0, suggesting a potential 94.04% downside.</li>
<li>Analysts currently favor an Buy trajectory for Zevra Therapeutics, with an average 1-year price target of $22.0, suggesting a potential 31.03% upside.</li>
<li>Analysts currently favor an Buy trajectory for EyePoint Pharmaceuticals, with an average 1-year price target of $27.33, suggesting a potential 62.78% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for Tilray Brands, Zevra Therapeutics and EyePoint Pharmaceuticals, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eton Pharmaceuticals</td>
<td>Buy</td>
<td>59.26%</td>
<td>$6.48M</td>
<td>-2.96%</td>
</tr>
<tr>
<td>Tilray Brands</td>
<td>Neutral</td>
<td>-1.36%</td>
<td>$52.01M</td>
<td>-25.45%</td>
</tr>
<tr>
<td>Zevra Therapeutics</td>
<td>Buy</td>
<td>-6.79%</td>
<td>$10.68M</td>
<td>-65.31%</td>
</tr>
<tr>
<td>EyePoint Pharmaceuticals</td>
<td>Buy</td>
<td>-17.39%</td>
<td>$10.77M</td>
<td>-14.91%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Eton Pharmaceuticals ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity.
<h3>Unveiling the Story Behind Eton Pharmaceuticals</h3>
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
<h3>Unraveling the Financial Story of Eton Pharmaceuticals</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Eton Pharmaceuticals displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 59.26%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Eton Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -5.13%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Eton Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2.96% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Eton Pharmaceuticals's ROA excels beyond industry benchmarks, reaching -1.07%. This signifies efficient management of assets and strong financial health.
Debt Management: Eton Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 1.22, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/ETON/earnings">To track all earnings releases for Eton Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ETON

A Look Ahead: Eton Pharmaceuticals's Earnings Forecast

Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Herbalife to report an earnings per share (EPS) of $0.41.
The market awaits Herbalife's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.14 in the last quarter, leading to a 42.7% increase in the share price on the following day.
Here's a look at Herbalife's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.41</td>
<td>0.22</td>
<td>0.35</td>
<td>0.41</td>
<td>0.34</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.59</td>
<td>0.36</td>
<td>0.57</td>
<td>0.54</td>
<td>0.49</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-8.0%</td>
<td>43.0%</td>
<td>11.0%</td>
<td>-9.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747058577_0.png" alt="eps graph" />
<h3>Tracking Herbalife's Stock Performance</h3>
Shares of Herbalife were trading at $6.73 as of May 09. Over the last 52-week period, shares are down 36.34%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/HLF/earnings">To track all earnings releases for Herbalife visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look Ahead: Herbalife's Earnings Forecast

INNO HOLDINGS INC. ("INNO" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INHD#NASDAQ">INHD</a>) is trade-focused building technology and electronic products trading company, dedicated to consistently seeking innovative ways to enhance services and technologies and delivers high-quality products to its customers.
INNO has announced strategic cooperation with New Life Technology Development Co Ltd ("New Life Tech"), a renowned electronic products supply chain management group in Hong Kong, on development of a cutting edge B2B marketplace platform that will facilitate manufacturers and distributors to sell direct to business buyers. This marketplace platform, empowered by cloud computing, big data, and high-frequency matchmaking technology, will provide sellers cutting edge marketplace technology to enhance and grow their business while offering buyers access to an exclusive collection of top brands at or below wholesale prices.
The strategic cooperation between INNO and New Life Tech signifies a strategic step forward in collaboration, particularly within the domain of electronic products supply chain services. This collaboration also opens avenues for exploration and innovation in various business sectors for INNO.

INHD

INNO Announces Strategic Cooperation With New Life Tech On Development Of Cutting Edge B2B Marketplace Platform

Guggenheim analyst Jonathan Lee reiterates DXC Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) from Neutral to Neutral.

Guggenheim Reiterates Neutral on DXC Technologyto Neutral

Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-13. Here's what investors need to know before the announcement.
Analysts estimate that Intuitive Machines will report an earnings per share (EPS) of $-0.05. 
Anticipation surrounds Intuitive Machines's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $2.00, leading to a 4.46% drop in the share price on the subsequent day.
Here's a look at Intuitive Machines's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.08</td>
<td>-0.01</td>
<td>-0.25</td>
<td>0.27</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-2.08</td>
<td>-0.83</td>
<td>0.29</td>
<td>-2.70</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.0%</td>
<td>21.0%</td>
<td>-2.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747058555_0.png" alt="eps graph" />
<h3>Performance of Intuitive Machines Shares</h3>
Shares of Intuitive Machines were trading at $9.24 as of May 09. Over the last 52-week period, shares are up 70.72%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/LUNR/earnings">To track all earnings releases for Intuitive Machines visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LUNR

An Overview of Intuitive Machines's Earnings

AmpliTech Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>, AMPGW))), a leading designer, developer, and manufacturer of advanced signal processing components for satellite, public and private 5G, and other communications networks, including full 5G/6G system design and global distribution of integrated circuit assembly packages and lids, today proudly announces a significant milestone: the FCC Certification of its cutting-edge ORAN LPRU-Gen3-3537-AE-AI 5G radios. This achievement marks a pivotal moment for AmpliTech Group as it further solidifies its strategy to position the company as an ORAN 5G leader in the global 5G market.
The FCC Certification for ORAN LPRU-Gen3-3537-AE-AI radios underscores AmpliTech's commitment to innovation and excellence in telecommunications. These state-of-the-art radios are designed to meet the rigorous standards of performance, reliability, and regulatory compliance set by the Federal Communications Commission, ensuring seamless integration into next-generation 5G networks.

AMPG

AmpliTech Group Achieves Major Milestone With FCC Certification Of Advanced ORAN LPRU-Gen3-3537-AE-AI 5G Radios

DoubleDown Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDI#NASDAQ">DDI</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate DoubleDown Interactive to report an earnings per share (EPS) of $0.55.
Investors in DoubleDown Interactive are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
The company's EPS beat by $0.13 in the last quarter, leading to a 7.31% drop in the share price on the following day.
Here's a look at DoubleDown Interactive's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.59</td>
<td>0.56</td>
<td>0.49</td>
<td>0.48</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.72</td>
<td>0.51</td>
<td>0.67</td>
<td>0.61</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-7.000000000000001%</td>
<td>-5.0%</td>
<td>-1.0%</td>
<td>9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747058546_0.png" alt="eps graph" />
<h3>Tracking DoubleDown Interactive's Stock Performance</h3>
Shares of DoubleDown Interactive were trading at $10.96 as of May 09. Over the last 52-week period, shares are up 0.97%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/DDI/earnings">To track all earnings releases for DoubleDown Interactive visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For DoubleDown Interactive

Barclays analyst Adrienne Yih maintains Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) with a Overweight and lowers the price target from $254 to $223.

Barclays Maintains Overweight on Dick's Sporting Goods, Lowers Price Target to $223

Landstar System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTR#NASDAQ">LSTR</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Landstar System to report an earnings per share (EPS) of $0.96.
The market awaits Landstar System's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings Track Record</h3>
The company's EPS missed by $0.03 in the last quarter, leading to a 3.46% drop in the share price on the following day.
Here's a look at Landstar System's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.34</td>
<td>1.45</td>
<td>1.45</td>
<td>1.28</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.31</td>
<td>1.41</td>
<td>1.48</td>
<td>1.32</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>-2.0%</td>
<td>-2.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747058536_0.png" alt="eps graph" />
<h3>Performance of Landstar System Shares</h3>
Shares of Landstar System were trading at $135.56 as of May 09. Over the last 52-week period, shares are down 20.8%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Analyst Views on Landstar System</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Landstar System.
Analysts have given Landstar System a total of 8 ratings, with the consensus rating being Neutral. The average one-year price target is $142.38, indicating a potential 5.03% upside.
<h3>Analyzing Ratings Among Peers</h3>
The below comparison of the analyst ratings and average 1-year price targets of Ryder System, Schneider National and Knight-Swift, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Ryder System, with an average 1-year price target of $163.0, suggesting a potential 20.24% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Schneider National, with an average 1-year price target of $24.5, suggesting a potential 81.93% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Knight-Swift, with an average 1-year price target of $50.82, suggesting a potential 62.51% downside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
The peer analysis summary presents essential metrics for Ryder System, Schneider National and Knight-Swift, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Landstar System</td>
<td>Neutral</td>
<td>0.41%</td>
<td>$153.79M</td>
<td>4.65%</td>
</tr>
<tr>
<td>Ryder System</td>
<td>Neutral</td>
<td>0.71%</td>
<td>$616M</td>
<td>3.20%</td>
</tr>
<tr>
<td>Schneider National</td>
<td>Neutral</td>
<td>6.28%</td>
<td>$116.40M</td>
<td>0.87%</td>
</tr>
<tr>
<td>Knight-Swift</td>
<td>Neutral</td>
<td>0.10%</td>
<td>$246.20M</td>
<td>0.43%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Landstar System ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the lowest Return on Equity. Overall, Landstar System is positioned in the middle compared to its peers in the analysis.
<h3>Unveiling the Story Behind Landstar System</h3>
Landstar System is an agent based asset-light third-party logistics provider focused on domestic truck brokerage. Historically, around half of its truck transportation freight is hauled by leased owner-operators with the remainder hauled by third-party broker-carriers. To a smaller degree, it offers intermodal, global air and ocean forwarding, and warehousing services. Landstar also runs a small business that offers insurance programs to captive owner-operators. It has a long history of industry-leading execution and operating profitability.
<h3>Financial Insights: Landstar System</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Landstar System's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 0.41%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Landstar System's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 3.82%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.65%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Landstar System's ROA excels beyond industry benchmarks, reaching 2.59%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.17, Landstar System adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/LSTR/earnings">To track all earnings releases for Landstar System visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LSTR

What to Expect from Landstar System's Earnings

Press Releases

BrightSpring Health Services Announces CareMed Was Selected as a National Specialty Pharmacy Partner for Leqembi®

BrightSpring Health Services, Inc. to Participate in Two Upcoming Investor Conferences

Health Care

BrightSpring Health Services Announces Onco360® Has Been Selected as a Partner for Several New Drugs

BrightSpring Health Services, Inc. Announced Refinancing of Term Loan B

BrightSpring Health Services, Inc. Enters into Definitive Agreement to Divest Community Living Business to Sevita; Reports Preliminary 2024 Financial Results and Provides 2025 Guidance Excluding Community Living

BrightSpring Health Services, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Management

BrightSpring Health Services, Inc. Announces Promotion of Jennifer Phipps to Chief Financial Officer

BrightSpring Health Services, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Increases Full Year 2025 Guidance

BrightSpring Health Services, Inc. to Announce First Quarter 2025 Financial Results on May 2, 2025

BrightSpring Health Services, Inc. Reports First Quarter 2025 Financial Results and Increases Full Year 2025 Guidance

BTSG

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

BrightSpring Health

Notizie

Ultime notizie per BrightSpring Health (NASDAQ:BTSG) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO